Literature DB >> 35116

Tardive dyskinesia--reversible and persistent.

D V Jeste, S G Potkin, S Sinha, S Feder, R J Wyatt.   

Abstract

Twenty-one hospitalized patients over 50 years of age who had tardive dyskinesia were studied for 13 months. After withdrawal of neuroleptics and antidepressants for three months, dyskinetic symptoms abated in 12 patients and persisted in nine. Discriminant function analysis showed that the persistent and reversible dyskinesia groups could be clearly separated and that the best discriminator was the number of drug-free intervals. The persistent dyskinesia group had had significantly longer neuroleptic treatment (mean, 10.8 yr) and a greater number (mean, 5.6) of drug interruptions of at least two months' duration each than did the reversible dyskinesia group. Our finding, as well as the literature reviewed, does not support the commonly held notion that frequent lengthy interruptions of long-term drug treatment reduce the incidence of persistent dyskinesia, at least in patients who are otherwise predisposed to the development of tardive dyskinesia.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 35116     DOI: 10.1001/archpsyc.1979.01780050095012

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  23 in total

1.  Neurobiological characterization of bipolar affective disorders : a focus on tardive dyskinesia and soft neurological signs in relation to serum dopamine Beta hydroxylase activity.

Authors:  U Goswami; S Basu; U Khastgir; U Kumar; R Chandrasekaran; B N Gangadhar; R Sagar; J S Bapna; S M Channabasavanna; P B Moore; I N Ferrier
Journal:  Indian J Psychiatry       Date:  1998-07       Impact factor: 1.759

2.  Abnormal involuntary movements: side-effect of neuroleptic drugs.

Authors:  L K Oyewumi
Journal:  Can Fam Physician       Date:  1982-01       Impact factor: 3.275

Review 3.  Management of tardive dyskinesia: current update.

Authors:  G M Simpson; E H Pi; J J Sramek
Journal:  Drugs       Date:  1982-05       Impact factor: 9.546

4.  Treatment schedule as a determinant of the development of tolerance to haloperidol.

Authors:  R J Carey; J DeVeaugh-Geiss
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

5.  Progressive changes in the acute dyskinetic syndrome as a function of repeated elicitation in squirrel monkeys.

Authors:  R Neale; S Gerhardt; S Fallon; J M Liebman
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

Review 6.  Pharmacologic features and effects of neuroleptics.

Authors:  M V Seeman
Journal:  Can Med Assoc J       Date:  1981-10-15       Impact factor: 8.262

7.  Effect of alpha lipoic acid on the tardive dyskinesia and oxidative stress induced by haloperidol in rats.

Authors:  Santhrani Thaakur; G Himabindhu
Journal:  J Neural Transm (Vienna)       Date:  2009-05-15       Impact factor: 3.575

8.  Bauhinia forficata prevents vacuous chewing movements induced by haloperidol in rats and has antioxidant potential in vitro.

Authors:  Luis Ricardo Peroza; Alcindo Busanello; Caroline Queiroz Leal; Jivago Röpke; Aline Augusti Boligon; Daiane Meinerz; Milena Libardoni; Margareth Linde Athayde; Roselei Fachinetto
Journal:  Neurochem Res       Date:  2013-02-02       Impact factor: 3.996

9.  Effect of different neuroleptics in tardive dyskinesia and parkinsonism. A video-controlled multicenter study with chlorprothixene, perphenazine, haloperidol and haloperidol + biperiden. Nordic Dyskinesia Study Group.

Authors: 
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

10.  Cytotoxic effects of neuroleptic drugs.

Authors:  W H Munyon; R Salo; D F Briones
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.